Becaplermin - BlackBoxRX.com

Becaplermin

An increased risk of mortality secondary to malignancy was observed in patients treated with three or more tubes of becaplermin gel in a post-marketing retrospective cohort study.
This drug should only be used when the benefits can be expected to outweigh the risks.
This drug should be used with caution in patients with known malignancy [See Contraindications and WARNINGS]

Updated July 2009

Disclaimer: This information presents a SUMMARY of Black Box data from product information labeling and does not address additional warnings, precautions, or other important safety data in the product insert. Patient care decisions SHOULD NOT be made without reviewing the most recent product information insert, which may be obtained from the manufacturer. This table may not be complete as it was prepared using product information from package inserts. It is periodically updated with supplemental information from FDA safety alerts, the FDA labeling announcements, and new drug approvals.

Formweb is a product of Formulary Productions, LLC. Visit our website at www.formweb.com for more information on online formularies featuring Black Box Warnings.
901-767-3000